In the wave of scientific and technological innovation, on November 18, 2024, Yuanwu Medicine signed a strategic cooperation agreement with Director Wu Bo of General Surgery Department of Shanghai City Sixth People's Hospital.

The two sides will make full use of their respective advantages to reach in-depth cooperation in cell development and differentiation methods, in vitro functional testing technology development, model animal development, cell drug research and development, quality standards, etc., and are committed to jointly creating and exploring new applications of iPSC technology in the treatment of metabolic system diseases. Field, promote safe, effective and accessible stem cell drugs into clinical practice.

Wu Bo, Director of General Surgery Department of Shanghai City Sixth People's Hospital, Ouyang Ping, founder and chairman of Yuanwu Medical, and Dr. Jin Jun, General Manager and CTO, attended the meeting. Professor Wang Hongbing, doctoral supervisor of the School of Life Sciences and Technology, Tongji University, and Professor He Zhiying, a researcher and doctoral supervisor of the Institute of Advanced Study in Translational Medicine, Tongji University, and other special guests witnessed the signing of the contract.

The Sixth People's Hospital of Shanghai City integrates clinical practice, scientific research and teaching. It is a leading research hospital in the country and even the world. It leads biomedical transformation, promotes cross-cooperation in multiple fields, and has made a lot of original contributions in clinical diagnosis and treatment, scientific research, etc.

Yuanwu Medical is a regenerative medicine company focusing on the development and application of iPSC(Induced Pluripotent Stem Cell) technology. iPSC technology is hailed as the third medical revolution after drug treatment and surgical treatment, and has shown great potential in the treatment of chronic degenerative diseases. The company's current pipeline indications are Parkinson's disease and osteoarthritis, both of which have entered the animal experimental stage.

Director Wu Bo said that as a clinician, we have found that there are still a large number of unmet clinical needs. This year marks the 120th anniversary of the founding of the Shanghai Sixth Hospital. We hope to take this opportunity to strengthen the leadership of scientific and technological innovation and open up new tracks to cultivate new quality productivity. Yuanwu Medicine was chosen because it has its own unique advantages in terms of core technology, professional team, scientific research capabilities, etc., and both parties have a common goal: to "start with the end" and open up the transformation from laboratory to clinical practice. road.

Chairman Ouyang Ping of Yuanwu Medicine emphasized that the Sixth People's Hospital of Shanghai City has rich experience in scientific research, clinical practice and transformation of scientific and technological achievements. This cooperation will help Yuanwu Medicine achieve new breakthroughs in innovation transformation and clinical application, discover the most realistic and accurate clinical needs, and provide new cure solutions for metabolic diseases. Today, when the world is facing a "wave of aging", this has very great social significance and economic value.

First from left: Professor Wang Hongbing, doctoral supervisor of the School of Life Science and Technology, Tongji University

Second from left: Ouyang Ping, founder and chairman of Yuanwu Medicine

Middle: Wu Bo, Director of General Surgery Department of Shanghai City Sixth People's Hospital

Second from right: Professor He Zhiying, researcher and doctoral supervisor of the Institute of Advanced Study in Translational Medicine, Tongji University

First from the right: Dr. Jin Jun, General Manager and CTO of Yuanwu Medicine

Moving forward steadily and healing the future

We keep pace with the times, deeply analyze market trends, and capture every fleeting opportunity with keen insight. We believe that only by continuous innovation can we move forward steadily in the face of challenges and heal the future.

This cooperation is not only a reflection of both sides 'deep understanding and common pursuit of scientific and technological innovation and industrial development, but also demonstrates both sides' commitment to social responsibilities and their firm determination to promote scientific and technological progress. Through resource sharing and innovation collaboration, we will jointly create an ecological chain of "industry-university-research and medicine", and hope that cutting-edge cell therapy technology represented by iPSC will bring transformative therapies to patients with chronic degenerative diseases around the world.

About Yuanvore Medicine

Shanghai Yuanwu Medical Technology Co., Ltd. is a regenerative medicine company focusing on the development and application of iPSC(Induced Pluripotent Stem Cell) technology. It is certified as a national-level technology-based small and medium-sized enterprise. It has a world's leading independent intellectual property rights in three key areas: cell reprogramming, directed differentiation, and cell engineering. It provides solutions for iPSC technology to treat chronic degenerative diseases in regenerative medicine.

In addition, Yuanwu Medical won the winning prize in the 13th China Innovation and Entrepreneurship Competition Disruptive Technology Innovation Competition (Future Health Field Competition) sponsored by the Ministry of Industry and Information Technology, was selected into the "2024 China Biotechnology Innovation Conference Outcome Compilation" of the China Biotechnology Development Center and participated in the conference roadshow.

"Yuan" is the beginning, and one yuan produces three;"Wu" soil is solid and heavy, giving birth to all things. Yuanwu Medicine uses stem cells as carriers to explore the secrets of life. iPSC provides unlimited possibilities for regenerative medicine with its unique infinite proliferation ability and developmental totality. Together with the world's leading iPSC expert team, we are committed to creating the "Yuanwu Plan". Starting from the concept of "the right cell plays the right function", we use small molecules to regulate cell destiny, accurately obtain target phenotypic cells while improving target cell productivity, provide industrial-friendly regenerative medicine solutions for the treatment of chronic degenerative diseases, and apply empowerment to major health fields such as aging, degradation, and damage, creating disruptive medical value and market value.